Rigosertib sodium is under clinical development by Onconova Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Rigosertib sodium’s likelihood of approval (LoA) and phase transition for Esophageal Squamous Cell Carcinoma (ESCC) took place on 31 May 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Rigosertib sodium Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Rigosertib sodium overview

Rigosertib (Estybon, ON 01910.Na and SyB L-1101) is under development for the treatment of metastatic kirsten rat sarcoma positive (KRAS+) lung adenocarcinoma, higher-risk myelodysplastic syndromes (MDS), skin squamous cell carcinoma, cervical squamous cell carcinoma, penile squamous cell carcinoma, recessive dystrophic epidermolysis bullosa associated locally advanced/metastatic squamous cell carcinoma, and esophageal squamous cell carcinoma, human papillomavirus (HPV) associated cancer, chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia, neuroblastoma, metastatic melanoma, colorectal cancer, clear cell renal cell carcinoma, rhabdomyosarcoma and non small cell lung cancer. It is a administered orally and intravenously. It acts by targeting phosphoinositide 3-kinase (PI3K) and polo-like kinase (PLK). It was also under development for the treatment of metastatic pancreatic cancer, ovarian cancer, mantle cell lymphoma, refractory/relapsed multiple myeloma, refractory/relapsed chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia and hairy cell leukemia. It was also under development for acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), myeloproliferative neoplasms including myelofibrosis, essential thrombocythemia and Polycythemia Vera.

Onconova Therapeutics overview

Onconova Therapeutics (Onconova) is a biopharmaceutical company that discovers and develops small molecule drug candidates for the treatment of cancer. The company’s drug candidates include rigosertib and ON123300. It develops drug candidates that target cancer and protect healthy cells based on its proprietary chemistry platform and cell-based differential screening. Onconova’s rigosertib is targeted at meeting the medical needs of patients with myelodysplastic syndromes. The company’s recilisib is used to treat the effects of acute radiation syndromes such as cytopenia. It partners with biopharmaceutical companies and medical organizations in the US. Onconova is headquartered in Newtown, Pennsylvania, the US.

Quick View Rigosertib sodium LOA Data

Report Segments
  • Innovator
Drug Name
  • Rigosertib sodium
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Dermatology
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.